Spectrum Pharmaceuticals Inc Announces Additional Extension Of Tender Offer Period For Shares Of Allos Therapeutics, Inc.

Spectrum Pharmaceuticals Inc and Allos Therapeutics, Inc. announced that Spectrum has provided an additional extension of the offer period in connection with tender offer to purchase all of the outstanding shares of common stock of Allos for $1.82 per share in cash, without interest and less any applicable withholding taxes. The extension was made in order for Spectrum and Allos to continue cooperating with the Federal Trade Commission (FTC) in relation to the previously announced Request for Additional Information and Documentary Material that each party received on May 9, 2012 from the FTC under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, applicable to the acquisition of Allos by Spectrum. The offer, which was previously scheduled to expire at 5:00 p.m., Eastern time, on August 6, 2012, has been extended until 5:00 p.m., Eastern time, on August 20, 2012, unless extended for an additional period. All terms and conditions of the tender offer shall remain unchanged during the extended period.